The drug is administered as an adjunct to diet and exercise therapy to improve glycemic control in patients with non-insulin dependent (type 2) diabetes mellitus.
1. The drug is administered as a monotherapy. 2. The drug is administered as a combination therapy in the following cases. - If metformin monotherapy does not provide sufficient glycemic control, this drug is administered in combination. - If a patient has not had previous diabetes drug treatment, and monotherapy is not sufficient for glycemic control, this drug is given in combination with metformin. - If combination therapy of metformin and sulfonylurea does not provide sufficient glycemic control, this drug is administered in combination. - If insulin therapy (insulin alone or combined with metformin) does not provide sufficient glycemic control, this drug is administered in combination.
Active Ingredient and Capacity
Gemigliptin 50 mg
Appearance & Packaging Unit Lemon-shaped orange film-coated tablet 56 tablets/PTP(14 tablets/PTP x 4), 300 tablets/bottle
Storage In a tight container, store at room temperature (1~30℃)
When you visit our website, information is stored in your browser or exported in the form of cookies. This information may be about you, your preferences, or the device you use, and is most often used to ensure that the website works properly. This information does not identify you directly, but it can offer a more optimized experience as you navigate our website. Because we respect your right to privacy, you may choose not to allow certain types of cookies. You can check the detailed settings and change them according to your needs.
This website uses technical cookies that are essential for using all of its features. They perform specific functions required to ensure your normal navigation of the site.
- Amazon Web Service
- Web Application Server
- Identifies whether the user checked "Do not see again today" in the pop-up window on the main page of the site
- Identifies whether the user participated in customer surveys
These cookies collect information about how visitors use the website to help improve the site. For example, we anonymously collect information such as the visitor’s device, access area, and time of visit.
These cookies balance the server load and maintain user sessions.
AWSALB, AWSALBCORS, AWSALBTG, AWSALBTGCORS
Browser type, browser version, operating system, authentication and security credentials, links inserted in e-mails viewed or clicked through AWS, device type, time and number of livestreams and downloads, Internet service provider, time zone, network connection type, device information, geolocation, playback details, page response time, content downloaded from AWS, download error, page interaction, content interaction, interaction or communication with AWS, browser plug-ins, cookies, cookie ID, mouse movement, click paths, phone number, content and ad views and interactions, usage data, IP address, accessed applications, full URL clickstream (including date and time) from or through the AWS website, streams, number of visits and interactions with AWS offerings
AWSALB, AWSALBCORS, AWSALBTG : 6 days AWSALBTGCORS : 7 days
Recipients of data
Amazon Web Services Inc., Amazon Web Services EMEA SARL